30 closest matches · ranked by relevance
Hypertension · Dyslipidemias · Diabetes
Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…
Cancer
Primary: Differences in Change in Daily Average of Moderate and Vigorous Physical Activity (MVPA) Levels Between Groups — -2.58; -2.12; -7.78 minutes — p=0.90
Health Insurance · Childhood Cancer Survivors
Primary: Acceptability of the Health Insurance Navigation Program — 8.9 units on a scale
Cancer Survivor
Primary: Feasibility as Measured by Study Enrollment Rates, Retention Rates, Adherence to the Intervention, and Reasons for Study Drop Out. — 20; 11; 8; 0 Participants
Acute Lymphoblastic Leukemia · Brain Tumors
Primary: Brain White Matter Volume for Patients Versus Sibling Controls — 27; 30.3 percentage — p=<.0001
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Cardiovascular Disease · Childhood ALL · Childhood NHL
Primary: Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months — -0.5; -3.4 percentage change
Cancer · Pediatric Cancer
Primary: Survivor Care Knowledge Scale — 10.6; 11.2 score on a scale
Childhood Cancer Survivors
Primary: Feasibility Measure: Enrollment (Young Adult Survivors) - Number of Eligible Patients Consented and Completing Baseline — 50; 29 Participants
Breast Neoplasms · Early Detection of Cancer
Primary: Percentage of Women Who Completed a Breast MRI and Mammogram — 8.9; 22.0; 17.8 percentage of participants — p=0.019
Pediatric Cancer · Quality of Life
Primary: Symptom Screening in Pediatrics Tool (SSPedi) Total Score — 7.9; 11.4 Score on a scale
Survivorship · Fatigue
Primary: Feasibility of the Technology-enhanced Fitness Program — 25; 24 Participants
Childhood Cancer · Insomnia · Neurocognitive Impairment
Primary: Change in Insomnia Severity Index (ISI) Scores From Baseline to Post-Intervention (Approximately 10 Weeks After Baseline) — -6.30; -3.91 Score on a scale
Cancer · Young Adult · Pain
Primary: Intervention Satisfaction: Satisfaction With Therapy and Therapist Scale-Revised (STTS-R) — 26.71; 27.33; 28.86; 27.75 scores on a scale — p=0.519
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Quality of Life · Cancer
Primary: Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality — 33.1; 14.8; 30.7; 18.9 percentage of…
Bone Mineral Density · Bone Strength
Primary: Percent Change in Total Bone Mineral Content (BMC) Per Height Compared Between Intervention and Placebo Groups — 2.72; 3.96 % change in grams/cm — p=0.69
Cancer
Primary: Feasibility of Intervention Measure (FIM) AYA — 4.52 units on a scale
Obesity · Cancer
Primary: Satisfaction and Exit Survey Composite Scale Score -- ONLY CAREGIVERS COMPLETED THIS MEASURE — 46.2; 37.5 units on a scale — p=<.05
Breast Cancer · Colorectal Cancer
Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance
Cancer Survivor · Prevention of Human Papillomavirus Infection
Primary: Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey]) — 179 Participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Physical Activity · Neoplasms · Cancer
Primary: Accrual Rate — 12 Participants per month
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Acute Lymphoblastic Leukemia
Primary: Feasibility of At Home tDCS Intervention — 25 Participants
Lung Cancer
Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants